BioSpace News Archive

It was another busy week of clinical trial announcements. Here’s a look.

Nanjing Bioheng Biotech Co., Ltd. Announced UCAR T cell therapy product targeting CD7, code CTD401, received Orphan Drug Designation from the U.S. Food and Drug Administration for the treatment of T-cell acute lymphoblastic leukemia.

Innovent Biologics, Inc., a world-class biopharmaceutical company that develops, manufactures and commercializes high quality medicines for the treatment of cancer, metabolic, autoimmune and other major diseases, announced that data from the ORIENT-32 study have been published in The Lancet Oncology.

COVID-19 patients suffer from cognitive and behavioural problems two months after being discharged from hospital, a new study presented at the 7th Congress of the European Academy of Neurology has found

Prestige BioPharma Limited specializing in the development of antibody therapeutics, announced that French National Agency for the Safety of Medicines and Health Products has approved a Phase 1/2a clinical trial of its first-in-class anti-PAUF monoclonal antibody, PBP1510, for the treatment of pancreatic cancer.